Navigation Links
Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry

bles companies to achieve world-class business performance. By leveraging the comprehensive database of The Hackett Group, Answerthink's business and technology solutions help clients significantly improve performance and maximize returns on technology investments. Capabilities include benchmarking, business transformation, business applications, business intelligence, and offshore application development and support. Founded in 1997, Answerthink has offices throughout the United States and in Europe and Asia. Answerthink was named the SAP 2006 SME Partner of the Year.

About LORENZ Life Sciences Group

LORENZ Life Sciences Group (www.lorenz.cc) develops and markets software solutions for the Life Sciences market. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management. As the number one supplier of submission management systems in the world for US, European and Japanese submissions, LORENZ is currently the market leader in producing eCTDs. With over 100 installations in 20 countries, LORENZ has built a reputable customer base.

Copyright (C) 2007 Answerthink, Inc. All rights reserved. Answerthink and EzLifeSciences as well as their respective logos are trademarks or registered trademarks of Answerthink, Inc.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors that may cause Answerthink's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that impact such forward-looking statements include, among others, the ability of the alliance or the products, services, or practices mentioned in this release to deliver the desired effect, our ability to effectively integrate acquisitions into our operations, our ability to
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
Post Your Comments:
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... risk of certain types of cervical cancer. The study, ... reveals obesity and body fat //distribution are associated more ... study involved 124 women with adenocarcinoma, 139 with squamous ... control group. Adenocarcinomas involve cells from the walls of ...
... Syndrome is a severe injury to most or all of ... and often are on life support. //A new study finds ... ARDS after a trauma. ,ARDS is not a specific ... with a number of diseases including pneumonia, shock, sepsis and ...
... the larynx are diagnosed in the United States. About 5,000 ... taking away their voice box and communication, as they know ... back. ,For five years, five months and 13 days, ... forget, and that is something she says she will never ...
... who had very low birth weights are likely to ... others born at higher birth rates. //The study, conducted ... reports respiratory function is more drastically reduced with smoking ... with low birth weight, defined as weighing less than ...
... prevent bone loss may also help prevent prostate cancer from ... Kingdom indicates oral sodium clodronate may slow the spread of ... //This is a drug commonly used to prevent bone loss. ... about 85 percent of men. The researchers recruited 311 men ...
... Unlike the outbreak earlier this year, the next time ... public health systems, //says a report by the National ... chains of SARS transmission of were stopped, the virus ... to humans, the report says. ,"The wave of ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Return of SARS possible this fall 2
... excellent choice for orthopedic procedures. ... to 24" for the surgeon's ... quickly attach to any O.R. table. ... C-Arm access and stability. Optional ...
... and ultra versatile model angulates for ... adjust the height of the support ... single post, or double tee foot. ... physician comfort and stability. A convenient ...
... torso and leg sections of ... simultaneously lift body and legs. ... raises and lowers legs individually ... A wide range of adjustment ...
... The PROfx elevates the surgical table to ... by providing the perfect table complement for ... an integral role in the surgical process, ... skill of the surgeon to minimize the ...
Medicine Products: